An Analysis of SARC021

Brian A. Van Tine, MD, PhD, assistant professor, Washington University School of Medicine in St. Louis, discusses the SARC021 trial, which examined TH-302 in combination with doxorubicin versus doxorubicin alone to treat patients with locally advanced unresectable or metastatic soft tissue sarcoma.

Clinical Pearls:

• TH-302 is a hypoxia-released ifosfamide that has none of the side effects found in traditional ifosfamides.
• TH-302 appears to be well tolerated and provide patients with a better quality of life.
• Data from this trial have the potential to change the standard of care in sarcoma, Van Tine says.